Ibogaine is not classified as a controlled substance in Canada. It is not listed under the Controlled Drugs and Substances Act—the legislation that schedules psychoactive substances in this country. That is a materially different legal position from the United States, where ibogaine has been Schedule I since 1970, or the United Kingdom, where it is Class A. What it does not mean is that ibogaine ceremony here requires no oversight, no screening, and no medical involvement. The legal status is a threshold condition. The medical requirements are what actually determine whether a programme is safe.
This matters for anyone researching access to ibogaine treatment: whether they are a Canadian resident, an American looking for a legal option, or someone in a country where domestic access is foreclosed. The legal environment in Canada is what creates the access. What a programme does with that environment determines whether it is worth accessing.
Key facts
- Ibogaine is not listed under Canada's Controlled Drugs and Substances Act—it is not prohibited
- It is not approved for medical use in Canada; absence of scheduling is not the same as approval
- In the US, ibogaine has been Schedule I since 1970; in the UK it is Class A
- Ibogaine ceremony involves 12–24 hours of active experience with continuous cardiac monitoring
- An on-site physician and pre-ceremony EKG are required—absolute medical contraindications exist
- The 2023 Stanford Nature Medicine study found 88% reduction in PTSD symptoms at one month in 30 special operations veterans
What Ibogaine's Legal Status Actually Means in Canada
The Controlled Drugs and Substances Act categorises substances into schedules based on potential for abuse and medical utility. Ibogaine does not appear on any of these schedules. This means possessing or facilitating ibogaine ceremony in Canada does not constitute a criminal offence under the CDSA in the way it would in the United States or the United Kingdom.
Ibogaine is not approved for medical use by Health Canada. It has not been granted regulatory approval for any clinical indication. The absence of scheduling is not an approval—it means ibogaine occupies an unusual regulatory space: not explicitly prohibited, but without the formal approvals required for prescription drug use. Practitioners who facilitate ibogaine ceremony in Canada are operating within this space, which is why the nature of a given programme—its medical oversight, screening protocols, and professional infrastructure—matters considerably.
There is no general licence required to facilitate ibogaine ceremony in Canada, and there is no federal registry of ibogaine providers. This is a different situation from regulated medical treatments. It means that evaluating a programme requires looking directly at what it does, not at whether it holds a particular credential.
How Canada Differs from the United States and United Kingdom
For Americans considering ibogaine treatment, the most relevant comparison is legal access. In the US, ibogaine's Schedule I classification has effectively prohibited clinical research and therapeutic use for more than 50 years. The scheduling decision preceded most of the evidence that now exists—it was made in 1970, before the clinical literature on ibogaine's effects on addiction, PTSD, and treatment-resistant depression had been produced. The $50 million USD committed by four Texas universities—UTMB, UTHealth Houston, Texas A&M, and Baylor—to clinical ibogaine trials signals a shift in research interest, but it has not changed the scheduling status. Americans cannot legally access ibogaine treatment in the United States.
In the UK, ibogaine is classified as a Class A drug under the Misuse of Drugs Act 1971, meaning possession, supply, and production are criminal offences. Canada's position does not criminalise ibogaine use or possession. This is why a significant proportion of people who come to Transcend's programme travel from the US, the UK, and other countries where domestic access is legally foreclosed.
Whether Canada's regulatory position will persist indefinitely is not certain. Psychedelic research has expanded significantly in the past decade, and regulatory agencies in several countries are actively revisiting their approaches. For now, Canada remains one of the most accessible legal environments for ibogaine treatment in the world.
What a Legitimate Programme in Canada Includes
Legal status is not a quality guarantee. The absence of scheduling in Canada does not make all ibogaine programmes equal. Several qualities distinguish a programme operating with appropriate medical oversight from one that is not.
The minimum requirements for a legitimate ibogaine ceremony:
- An on-site physician throughout the 12–24 hour ceremony.Ibogaine blocks hERG potassium channels, which can prolong the QT interval on an EKG. The risk is highest in the first several hours of the experience. An on-site physician is not a paperwork requirement—it is the person who can respond if the cardiac situation changes during ceremony.
- Continuous cardiac ECG monitoring.QT prolongation and arrhythmia are the primary mechanisms responsible for ibogaine-related fatalities. Monitoring throughout the ceremony—not just at admission—is how a provider detects and responds to changes before they become emergencies.
- Pre-ceremony medical screening. This includes a 12-lead EKG, full blood panel, and complete medication review. These assessments cannot be completed on the day of ceremony or waived for otherwise healthy-seeming participants.
- A supervised recovery period.The active experience is 12–24 hours; the recovery period is 2–3 days. Participants are supported, monitored, and not left to manage independently during this time.
Any ibogaine provider who skips cardiac screening is not operating safely. The EKG is how you identify QT prolongation before ceremony, not during it. It costs little and answers a question that cannot be answered any other way. Providers who omit it are either unaware of the cardiac mechanism or choosing not to invest in it. Neither is acceptable.
The Medical Screening Requirements
Before any ceremony at Transcend, every participant completes the following:
A full medical history review, including all diagnosed conditions, past hospitalisations, and relevant family history.
A 12-lead EKG and cardiovascular assessment. QT interval is the primary concern. Normal range, in the context of ibogaine administration, requires confirmation from a physician with experience interpreting these values in this population. An EKG that looks unremarkable in another context may indicate a contraindication here.
A blood panelassessing liver function, kidney function, and a complete blood count. Ibogaine is metabolised primarily by the liver via CYP2D6 enzymes. Liver disease is an absolute contraindication. Kidney disease affects how noribogaine—ibogaine's active metabolite—is eliminated.
A complete medication review. Many psychiatric and cardiovascular medications are contraindicated with ibogaine, either through cardiac mechanism or serotonergic mechanism. Some require supervised tapers measured in months before ceremony can be discussed. See the full list of screening requirements for detail on specific medications.
A psychiatric history assessment. Active psychosis or schizophrenia-spectrum disorder is an absolute contraindication. Acute psychiatric crisis is a contraindication regardless of diagnosis.
This screening is not bureaucratic overhead. It is the difference between appropriate and inappropriate candidates—and, in some cases, between a ceremony and a fatality.
Who Is Not Right for This
Not everyone who applies is a candidate. Some people who contact Transcend have conditions that make ibogaine ceremony genuinely dangerous. Some are on medications that cannot be safely tapered within a reasonable timeframe. Some are in states of acute psychiatric instability that require a different kind of support before this work is appropriate.
The conversation that ends in “this is not the right path for you at this moment” is one of the most important things this work does. People in crisis who have found a thread of hope do not receive a “no” easily. Saying it directly, without cushioning, is an act of care—not rejection.
Absolute medical disqualifiers:
- QT prolongation or significant cardiac arrhythmia confirmed on baseline EKG
- Recent myocardial infarction or significant structural heart disease
- Severe liver or kidney disease
- Active psychosis or schizophrenia-spectrum disorder
- Pregnancy
- Lithium and certain other psychiatric medications
Medications requiring specific protocols before ceremony can be considered:
- Current SSRIs or SNRIs: physician-supervised taper to completion required. Ibogaine and serotonergic medications interact via the SERT receptor. The risk of serotonin syndrome is real and potentially fatal. No case is an exception to this rule—dose reduction is not sufficient. See the SSRI taper timeline for the specific washout requirements by medication.
- Methadone: a specific multi-month transition protocol is required. The cardiac risks of methadone and ibogaine overlap in mechanism; combined, they require careful sequential preparation rather than simply stopping one and starting the other.
Situational disqualifiers:
- Acute psychiatric crisis, regardless of urgency or the strength of the motivation to proceed
- No ability to access or commit to post-ceremony integration support
- Seeking a shortcut to insight or a novel experience rather than genuine engagement with the work
The people for whom ibogaine ceremony tends to produce lasting results are often those who have already spent years trying other approaches—SSRIs that blunted rather than resolved, therapy that circled without landing, abstinence programmes that held for a year and then didn't. By the time they arrive, they are not naive about difficulty. They have evidence from their own experience that the conventional options are not enough for them. That scepticism—earned through years of trying—tends to produce people who are genuinely ready to encounter what ibogaine produces.
The FAQ covers many of the specific questions about contraindications and what disqualifies a candidate. The 2023 Stanford Nature Medicine study documents the 88% reduction in PTSD symptoms at one month post-treatment in 30 special operations veterans—a population that had, by definition, already exhausted conventional approaches.
What Ibogaine Ceremony Costs in Canada
Ibogaine ceremony at Transcend costs $2,000–$5,000 CAD. This range reflects differences in what individual participants require. All ceremony fees include pre-ceremony medical screening, the on-site physician throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, facilitation, and the 2–3 day supervised recovery period on-site.
Integration coaching is separate: $150–$300 CAD per session(60–90 minutes), available in packages of three or more. The ceremony produces a window. Integration coaching is what supports the work done during that window.
For comparison: ibogaine treatment in Mexico ranges from approximately $4,000–$15,000 USD, with significant variation in what that price includes and what safety infrastructure is in place. In the US, ibogaine is not legally available. Canada's legal environment makes access possible without the criminal risk present in those jurisdictions—but it does not resolve the question of whether a given provider's safety standards are adequate. The cost of an on-site physician, proper EKG monitoring, and medical screening is real. Programmes charging significantly below market rate are almost always reducing safety infrastructure somewhere in the process.
A full breakdown of what affects pricing is in the ibogaine treatment cost in Canada post.
Is This Right for You?
The ceremony page describes what the active experience involves: the duration, the physical qualities of the experience, and what the 2–3 day recovery period looks like. The FAQ covers the most common questions about how the screening process works and what the timeline from application to ceremony typically involves. The integration page covers what the weeks and months following ceremony require, and what integration coaching supports during that period.
If you are not a candidate—a confirmed cardiac contraindication, a current medication that requires a supervised taper of several months, an acute state that requires a different kind of support first—you will be told that directly. That is not a failure of the intake process. It is the most accurate and useful thing the intake process can do for someone who is not yet in a position to proceed.
Applications are open. Every application receives a personal response within 2–3 business days.